Dually Active HIV/HBV Antiretrovirals Protect Against Incident Hepatitis B Infections: Potential for Prophylaxis.

Shilaih, Mohaned; Marzel, Alex; Scherrer, Alexandra U; Braun, Dominique L; Kovari, Helen; Rougemont, Mathieu; Darling, Katharine; Battegay, Manuel; Hoffmann, Matthias; Bernasconi, Enos; Hirzel, Cédric; Günthard, Huldrych F; Kouyos, Roger (2016). Dually Active HIV/HBV Antiretrovirals Protect Against Incident Hepatitis B Infections: Potential for Prophylaxis. Journal of infectious diseases, 214(4), jiw195. Oxford University Press 10.1093/infdis/jiw195

Preview	Text infdis.jiw195.full.pdf - Accepted Version Available under License Publisher holds Copyright. Download (863kB) | Preview
	Text infdis.jiw195.full.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (331kB)

BACKGROUND

Hepatitis-B virus (HBV) has a detrimental effect on HIV natural course, and HBV vaccination is less effective in the HIV infected. We examine the protective effect of dually active antiretroviral therapy (DAART) for HIV/HBV (Tenofovir/Lamivudine/Emtricitabine) in a large cohort encompassing heterosexuals, men-who-have-sex-with-men (MSM), and intravenous drug users (IDU), who are HIV-infected yet susceptible to HBV, with comprehensive follow-up data about risky behavior and immunological profile.

METHODS

We defined an incident HBV infection as the presence of any of HBV serological markers (HBsAg/AntiHBc/HBV-DNA) following a negative baseline AntiHBc test. Patients with positive AntiHBs were excluded. Cox proportional hazard models were utilized, with an incident case of HBV infection as the outcome variable.

RESULTS

We analyzed 1,716 eligible patients from the Swiss HIV Cohort Study with 177 incident HBV cases. DAART was negatively associated with incident HBV infection (hazard ratio 0.4, 95%CI 0.2-0.6). This protective association was robust to adjustment (0.3, 0.2-0.5) for condomless sex, √CD4 count, drug use, and patients' demographics. Condomless sex (1.9,1.4-2.6), belonging to MSM (2.7,1.7-4.2) or IDU (3.8,2.4-6.1) were all associated with higher HBV hazard.

CONCLUSIONS

Our study suggests that DAART, independently of CD4 count and risky behavior, has a potentially strong public health impact including pre-exposure prophylaxis of HBV co-infection.

Interest & Impact

Downloads

179 since deposited on 05 Jul 2016
18 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item